CATALOG of PROGRAMS ACCEPTED BY: CAP • CMS • COLA • TJC 2 800.333.0958 Technical Expertise

Total Page:16

File Type:pdf, Size:1020Kb

CATALOG of PROGRAMS ACCEPTED BY: CAP • CMS • COLA • TJC 2 800.333.0958 Technical Expertise Innovative Solutions. Technical Excellence. 2011 CATALOG OF PROGRAMS ACCEPTED BY: CAP • CMS • COLA • TJC 2 800.333.0958 www.api-pt.com Technical expertise. Responsive service. Constant innovation. We’re proficient at all of them. When it comes to proficiency testing, reliability is everything. You need a provider that fully supports you with technical expertise and prompt, personal service. At API, we work with over 16,000 laboratories, covering all areas of laboratory medicine. Impressive numbers, for sure. But our reputation as a leader has grown because we are committed to providing the best customer service in the industry. We handle each contact promptly and professionally, so you don’t wait for answers. Our technical experts fully understand the laboratory so they can assist you with a wide range of needs. We also provide creative online services and free Continuing Education Credits. The end result? With API, you have people and results you can rely on to meet all your proficiency testing needs. 800.333.0958 www.api-pt.com 3 Table of Contents Enrollment Information 5 Highlights for 2011 6 2011 Shipping Schedule 6 Proficiency Testing Programs Chemistry 7-13 Hematology 14-16 Andrology 16 Coagulation 17, 18 Urinalysis, PPM, and Other Tests 19, 20 Microbiology 21-25 Immunology 26, 27 Immunohematology 28 Supplemental Products 28 Additional Programs Remedial Proficiency Testing 29 Troubleshooting Samples 29 Secondary Instrument Programs 29 Continuing Education Credit 29 Index 30, 31 CAP Accepted Analyte List 30, 31 4 800.333.0958 www.api-pt.com If you have any questions or need assistance in ordering, please contact Customer Enrollment Info Service at 800-333-0958. Visit our website, api-pt.com, to view a participant summary. 1. Select the program options you need using this catalog. Use the order form to record your selections, then follow these instructions to complete the form. Make sure you include: a. Shipping Address (include mailing address for correspondence) b. Billing Address (if different than shipping address) c. Regulatory Information d. Payment Method 2. Be sure the “TOTAL” column includes the $75 annual fee which covers the administrative costs of setting up customer files, data processing, and reports. 3. To Order: a. Fax the order form to us at 231-941-7287, or b. Phone us at 800-333-0958 and speak with customer service, or c. Mail the order form to us. 4. After processing your order, we will send you an “Order Confirmation” showing products ordered and pre-set shipping dates. a. Mark your calendar with the shipment dates. If your kit does not arrive within 7 business days after the shipment, call us so we can trace the kit or issue a replacement. b. Inspect your kit immediately upon receipt. Call us within 3 days if any sample is missing or damaged; we will send you a replacement. Please call prior to discarding any damaged samples. c. Read the instructions carefully before beginning a test. Some samples require special handling before testing. d. Keep a copy of any result forms mailed to API. Partial Year Orders API makes every effort to accommodate new orders or order changes throughout the year. Except for the annual fee, we will prorate the prices for orders received after the first shipment. Cancellations We will refund any charges for unshipped specimens if we receive notification in writing four weeks prior to the next shipment date. The annual fee is nonrefundable. International and Non-Continental U.S. Customers Most countries require import permits or certificates of origin for clearance through customs. Import permits must be obtained by the laboratory receiving the product from API. Local authorities can tell you if any permits are required for your location. Additional shipping charges will be added to International and Non-Continental U.S. orders. Please go to www.api-pt.com for more information. 800.333.0958 www.api-pt.com 5 Highlights for 2011 API Proficiency Testing Programs are CAP Accepted! We are pleased to announce that the College of American Pathologists accepts proficiency testing programs from the American Proficiency Institute. This means CAP accredited laboratories can use API’s proficiency testing programs. Please refer to the index on pages 30 and 31 for a complete listing of CAP accepted analytes. API programs are also accepted by CMS, COLA, TJC, and state regulatory agencies. New and Enhanced programs for 2011 are: • Adenovirus • Hematology - for the Chempaq XBC or XDM Added to catalog #322, 942, & 933 on page 25 See catalog #243 on page 14 • Automated Urine Microscopy • Lp-PLA2 See catalog #270 & 271 on page 20 See catalog #148 on page 11 • Blood Culture • Procalcitonin See catalog #361 on page 23 See catalog #169 on page 9 • Campylobacter Antigen • Sperm, presence or absence See catalog #328 & 360 on pages 21, 22 Added to catalog #233 on page 19 • Cardiac Markers for Secondary Instruments • Urine Adulteration Test See catalog #C40 & C41 on page 29 See catalog #146 on page 13 • Ionized Calcium • Urine Sediment Microscopy Added to catalog #122 on page 7 Added to catalog #232 & 251 on pages 19 2011 Shipping Schedule The shipping dates are shown at the top of each page in this catalog. These dates will also be printed on your order confirmation. A general schedule is shown below. 1st Test Event 2nd Test Event 3rd Test Event Chemistry/Immunology/Immunohematology January 24 May 16 September 12 Hematology/Coagulation/Body Fluids March 21 July 11 November 7 Microbiology March 14 July 5 October 31 Creative Online Services Paperless Proficiency Testing™ has unique features that can help you manage your proficiency testing more efficiently. Visit www.api-pt.com to learn more. • Email is sent to you with shipping dates and package tracking information • Submit, review and print results online - reports saved online for at least 5 years • Confirmation that your results have been received when submitted online • Receive an email when your evaluations are ready to view online • Interactive performance reports help you quickly zero in on problem areas • Sample testing instructions, failures reports, and corrective action forms available online • Trend data and graphs • Participant data summaries available online • Free Continuing Education credits 6 800.333.0958 www.api-pt.com All analytes or modules in bold type are regulated for proficiency testing by CMS. They are designed for testing sites required by CLIA ‘88 to be enrolled in proficiency Chemistry testing. Each program is shipped 3 times a year with 5 samples, unless otherwise noted. 2011 Shipping Dates: January 24, May 16, September 12 Routine Chemistry Catalog # Program Additional Information 120 Chemistry 1 5 mL serum Bilirubin, total Glucose Cholesterol Triglycerides 121 Chemistry 2 5 mL serum ALT (SGPT) Glucose AST (SGOT) HDL Cholesterol Bilirubin, total LDL, calculated and measured Bilirubin, direct Potassium Cholesterol Sodium Chloride Triglycerides CO2 Urea Nitrogen (BUN) Creatinine Uric Acid 122 Chemistry 3 5 mL serum Albumin LDH Alkaline Phosphatase LDL, calculated and measured Alpha-fetoprotein Lipase ALT (SGPT) Magnesium Amylase Osmolality AST (SGOT) Phosphorus Bilirubin, direct Potassium Bilirubin, total Sodium Chloride Total Protein Calcium Theophylline Calcium, ionized TIBC, calculated and measured Cholesterol Triglycerides CO2 T Uptake Cortisol T3 Creatine Kinase (CK) Free T3 Creatinine Thyroxine (T4) GGT Free T4 Glucose TSH HCG, quantitative UIBC, measured HDL Cholesterol Urea Nitrogen (BUN) Iron Uric Acid Lactic Acid 141 Additional Chemistry For laboratories that need more sample volume; 5 mL; includes all analytes listed in Cat. #122 125 Thyroids, Cortisol & HCG 5 mL serum Alpha-fetoprotein Thyroxine (T4) TSH Free T4 T Updake Cortisol T3 HCG, quantitative Free T3 Analyte is not CAP accepted. See our website for updates. 800.333.0958 www.api-pt.com 7 Chemistry 2011 Shipping Dates: January 24, May 16, September 12 Therapeutic Drug Monitoring Catalog # Program Additional Information 132 Therapeutic Drugs 5 mL serum Acetaminophen Phenytoin Amikacin Primidone Carbamazepine Procainamide Digoxin Quinidine Ethosuximide Salicylates Gentamicin Theophylline Lithium Tobramycin N-acetylprocainamide Valproic Acid Phenobarbital Vancomycin 136 Therapeutic Drugs Reduced pricing if a Chemistry See Catalog #132 program is ordered (Cat. #120, 121, 122 or 125). For additional sample volume see Cat. #141 Cardiac Markers Catalog # Program Additional Information 140 Cardiac Markers Liquid samples, 1 mL BNP NT pro-BNP CK, total Troponin I CK-MB Troponin T Myoglobin 920 Cardiac Markers Liquid samples, 1 mL - 2 samples BNP Troponin I Myoglobin Troponin T NT pro-BNP 165 Additional Cardiac Markers For laboratories that need more sample volume, 1 mL 246 D-dimer - Quantitative For quantitative D-dimer methods – 2 D-dimer samples (Shipping dates March 21, July 11, Nov. 7) 425 High Sensitivity CRP For high sensitivity CRP procedures hsCRP that measure levels between 0 - 1.5 mg/dL – 2 samples Analyte is not CAP accepted. See our website for updates. 8 800.333.0958 www.api-pt.com Chemistry 2011 Shipping Dates: January 24, May 16, September 12 Blood Gas and Oximetry Catalog # Program Additional Information 111 Blood Gas 3 mL ampule pH pCO2 pO2 112 Blood Gas Plus 3 mL ampule; for combination blood pH Glucose gas / electrolyte analyzers (with or pCO2 Hematocrit without hematocrit option). pO2 Hemoglobin, calculated BUN Lactate Calcium, ionized Magnesium, ionized Chloride Potassium Creatinine Sodium 114 Blood Oximetry 2 mL ampule; hemoglobin source is Carboxyhemoglobin Methemoglobin bovine Hematocrit, calculated Oxyhemoglobin Hemoglobin, total Miscellaneous Chemistry Catalog # Program Additional Information 144 Waived Chemistry Albumin Creatinine 5 mL serum - 2 samples for Alkaline Phosphatase GGT laboratories performing these tests ALT (SGPT) Glucose using methods that are waived Amylase HDL Cholesterol AST (SGOT) LDL, calc. & measured Bilirubin, total & direct Phosphorus Calcium Potassium Chloride Sodium Cholesterol Total Protein CO2 Triglycerides Creatine Kinase (CK) Urea Nitrogen (BUN) Uric Acid 169 Procalcitonin Procalcitonin 2 lyophilized samples Analyte is not CAP accepted.
Recommended publications
  • Point-Of-Care Testing for Anticoagulation Monitoring In
    Point-of-Care Testing for Anticoagulation PATIENT SAFETY Monitoring in Neuroendovascular Procedures H.M. Hussein SUMMARY: POC testing is defined as diagnostic testing at or near the site of patient care. Rapid A.L. Georgiadis measurement of the intensity of anticoagulation and, more recently, platelet inhibition allows dose titration of adjuvant medications such a heparin and antiplatelet agents during neuroendovascular A.I. Qureshi procedures. However, knowledge among practicing physicians regarding the pathophysiologic basis of these measurements and variations in knowledge about the differences among devices is often limited. This review discusses the role of anticoagulation in endovascular procedures and the currently available POC tests for anticoagulation monitoring. ABBREVIATIONS: ACT ϭ activated clotting time; Anti-Xa ϭ quantitative chromogenic heparin assay; aPTT ϭ activated partial thromboplastin time; AT ϭ antithrombin; CI ϭ confidence interval; GP IIb/IIIa ϭ glycoprotein IIb/IIIa; Hemonox-CT ϭ Hemonox clotting time; HIT ϭ heparin-induced thrombocytopenia; HMT ϭ Heparin Management Test; IV ϭ intravenous; LMWH ϭ low-molecular- weight heparin; MI ϭ myocardial infarction; OR ϭ odds ratio; PCI ϭ percutaneous coronary intervention; POC ϭ point of care; UFH ϭ unfractionated heparin hromboembolism ensues from activation of platelets and Brief Overview of Anticoagulant Medications Tthe coagulation cascade and is a major source of compli- Anticoagulants reduce the activity of proteases in the coagula- cations during endovascular procedures. Multiple studies tion cascade. On the basis of their mechanism of action (Fig 1), have demonstrated accelerated platelet activation during cor- anticoagulants can be divided into 4 major groups: vitamin K onary and cerebral angioplasty.1,2 The coagulation cascade antagonists (warfarin), heparins (UFH and LMWH), direct (Fig 1) consists of a sequential conversion of a series of proen- thrombin inhibitors, and direct factor Xa inhibitors.
    [Show full text]
  • Anticoagulation of Children Undergoing Cardiopulmonary Bypass Is Overestimated by Current Monitoring Techniques
    PAPER Anticoagulation of Children Undergoing Cardiopulmonary Bypass Is Overestimated by Current Monitoring Techniques John T. Owings, MD; Marc E. Pollock, MD; Robert C. Gosselin, MT; Kevin Ireland, RN, CCP; Jonathan S. Jahr, MD; Edward C. Larkin, MD Hypothesis: Children who undergo cardiopulmonary reserve, fibrinogen; the natural antithrombotic, anti- bypass (CPB) are proportionally more hemodiluted than thrombin; and heparin concentration. adults who undergo CPB. Current methods of monitor- ing high-dose heparin sulfate anticoagulation are depen- Results: Ten children and 10 adults completed the study. dent on fibrinogen level. Because of the decreased fi- Children had lower fibrinogen levels than adults through- brinogen levels in children, current methods of monitoring out CPB (P,.05). All adults had both therapeutic ACT and heparin anticoagulation overestimate their level of anti- Heparin Management Test levels measured throughout coagulation. CPB. Although children had therapeutic ACT levels, their Heparin Management Test levels were subtherapeutic while Design: Prospective controlled trial. undergoing CPB. The children had significantly higher thrombin-antithrombin complexes and prothrombin Main Outcome Measure: Production of thrombin (ad- fragment F1.2 than adults, indicating ongoing thrombin equacy of anticoagulation). production (P,.01). The increases in thrombin- antithrombin complexes and prothrombin fragment F1.2 Methods: Children and adults undergoing cardiac sur- in children were inversely proportional to their weight. gery who received CPB were anticoagulated in the stan- dard fashion as directed by activated clotting time Conclusions: Children undergoing CPB with heparin (ACT) results. Each subject had blood sampled at base- dosing adjusted to optimize the ACT manifest inad- line; heparinization; start of the CPB; CPB at 30, 60, equate anticoagulation (ongoing thrombin formation).
    [Show full text]
  • P R O G R a M Guide
    2015 PROGRAM GUIDE APPROVED BY CLIA, COLA, JCAHO ACCEPTED BY THE COLLEGE OF AMERICAN PATHOLOGISTS 2015 Program Guide Cover - 14831PTS.indd 3 12/18/14 2:18 PM GENERAL TABLE OF CONTENTS 2015 Schedule…......................…………………………………………………………….…………….....................................................................................3 General Instructions……………………………………………………………………………….............................................................................................4-7 Online Reporting Instructions………………………………………………………………………………...............................................................................7-8 Reporting Form Instructions......................................................................................................................................................................9 Chemistry............................................................................................................................................................................................10-20 Specialty Programs…………………………………………………………………………..…………………………………………………………..………………………………19-20 Clinical Microscopy & Urinalysis.........................................................................................................................................................20-21 Coagulation.........................................................................................................................................................................................21-24 General Hematology Instructions............................................................................................................................................................24
    [Show full text]
  • Cathlab Hemochron Activated Clotting Time
    Provincial Health Services Authority Hemochron Activated Clotting Time Low Range Procedure for CathLab Identifier: CWPC ACT 0180 Version #: 2 Folder: CW POCT Type: Procedure (3yr) Subfolder: ACT Effective on: 2021-05-13 HEMOCHRON Activated Clotting Time Low Range Procedure for CathLab This procedure provides instructions on how to perform Activated Clotting Time (ACT) on the Hemochron® Signature Elite in settings of low to moderate heparin doses. The Hemochron® Signature Elite is a point-of-care coagulation testing system. When used with the Hemochron® Jr Low Range Activated Clotting Time (ACT-LR) cuvette, it provides a quantitative assay for monitoring heparin anticoagulation during various medical procedures when heparin is used. It is intended for use in monitoring low to moderate heparin doses frequently associated with procedures such as cardiac catheterization and Extracorporeal Membrane Oxygenation (ECMO). ACT values from different assays or instruments are NOT interchangeable. Do NOT switch between different types of ACT tests or methods when monitoring a patient. Use only the ACT- LR when low to moderate heparin doses are being administered. This method exhibits considerable variability and anticoagulation status should be assessed in concert with other clinical and laboratory features. Samples: Sample Collection The Hemochron® Jr ACT-LR test is performed using fresh whole blood. Collect samples as per clinical protocol. The Hemochron® Jr ACT-LR Cuvette employs a Celite activator and is intended for monitoring heparin therapy.
    [Show full text]
  • Chapter 4 HEMOSTASIS and BLOOD
    Chapter 4 HEMOSTASIS AND BLOOD TRANSFUSION Tony Chang, MD, Elizabeth Donegan, MD The infusion of blood and blood products from one individual to another to stop or prevent bleeding, provide adequate oxygen delivery, and to prevent death from hemorrhage saves millions of lives. Nevertheless, the practice of Transfusion Medicine remains in its infancy. In the 20th century, blood transfusion became a relatively safe and common practice, despite the relative absence of transfusion guidelines based on randomized, prospective controlled trials. Most transfusion practices are based on convention and convenience. The understanding of hemostasis, safe transfusion practices, appropriate testing of blood and blood products, as well as the consequences of transfusion continues to unfold. An understanding of these principles is very important for anesthetists who transfuse about half of the blood transfused in hospitals. Without this knowledge, transfusion practices often result in poor outcomes. This chapter will discuss the current understanding of hemostasis, laboratory tests that assist in the decision of which components or products to transfuse and when to transfuse. Current pediatric transfusion practices, and the laboratory collection, preparation, and testing of blood and blood components are included. HEMOSTASIS Hemostasis is now understood to be a complex system of checks and balances designed to prevent abnormal clotting and uncontrolled bleeding. Coagulation is a cell-based event initiated on the surface of endothelial cells, in the subendothelium, and on platelets (Figure 4-1). 87 Chapter 4: HEMOSTASIS AND BLOOD TRANSFUSION Figure 4-1: Coagulation Overview of coagulation: Coagulation is activated when endothelium is disrupted and blood contacts tissue factor (TF). TF activates factor VII in turn activators factor X, which in combination with factor V, forms the prothombinase complex.
    [Show full text]
  • Test Abbreviations
    TEST ABBREVIATIONS A1A Alpha-1 Antitrypsin CONABO Confirmatory Type A1c Hemoglobin A1c CPK Creatine Phosphokinase AB Antibody Cr Creatinine ABG Arterial Blood Gas CRCL, CrCl Creatinine Clearance ABRH ABO Group and Rh Type CRD Cord Type and DAT ABT Antibody Titer CREAT Creatinine ACA Anti-Cardiolipin Antibodies CRP C-Reactive Protein ACE Angiotensin Converting Enzyme Cu Copper ACID PHOS Acid Phosphatase D Bil Direct Bilirubin ACP Acid Phosphatase DAT Direct Antiglobulin (Coombs) Test ACT Activated Clotting Time DCAS DAT and AB Screen ACTH Adrenocorticotropic Hormone DHEA Dehydroepiandrosterone ADA Adenosine Deaminase DHEAS Dehydroepiandrosterone-Sulfate AFB Acid-Fast Bacillus DIFM Differential AFLM Amniostat Dig Digoxin AFP Alpha Fetoprotein EOS Eosinophils AG Antigen EPO Erythropoietin ALA Aminolevulinic Acid ERA Estrogen Receptor Assay Alb Albumin ESR Erythrocyte Sedimentation Rate Alk Phos Alkaline Phosphatase ETOH Ethanol ALP Alkaline Phosphatase FBS Fasting Blood Sugar (Glucose) ANA Antinuclear Antibody Fe Total Iron Anti-HBc Hepatitis B Core Antibodies FEP Free Erythrocyte Protoporphyrin Anti-HBe Hepatitis Be Virus Antibody FFN Fetal Fibronectin Anti-HBs Hepatitis B Surface Antibody Fol Folate Anti-HCV Hepatitis C Antibody FSH/LH FSH/LH Evaluation APT APT – Stool for Fetal Hemoglobin FT3 Free T3 aPTT Activated Partial Thrombin Time FT4 Free Thyroxine ASN Antibody Screen G2PP 2 Hour Postprandial Glucose ASO Antistreptolysin-O G-6-PD Glucose-6-Phosphate AT III Antithrombin-III Activity Dehydrogenase B12 Vitamin B12 Gamma GT Gamma Glutamyl
    [Show full text]
  • 2019 Surveys Catalog
    2019 Surveys and Anatomic Pathology Education Programs PERFORMANCE YOU CAN MEASURE. ACCURACY YOU CAN TRUST. The science of better PT. Proficiency Testing (PT) offerings from the CAP are supported by 600 experts in laboratory medicine serving on 32 scientific committees. These experts track testing trends, monitor technical advances, and work collaboratively with professional colleagues and medical specialty societies to improve the quality of testing. Through their efforts, PT programs from the CAP are based on the latest scientific information and reflect the current needs of laboratory medicine. This expertise not only drives improvements in the laboratory, it helps propel advancements in the in vitro diagnostics industry. CAP science in action: Improving Hemoglobin A1c PT The CAP has worked with the National Glycohemoglobin Standardization Program (NGSP) in tightening of the accuracy-based grading by using NGSP targets for the CAP Hemoglobin A1c PT. When the accuracy-based grading started in 2007, 15% was the initial acceptable limit. In 2019, we use 6%. In response to the tightened grading, the manufacturers have improved their assays and PT results are now more reflective of the patient results. This asw made possible by using fresh whole blood specimens in the Hemoglobin A1c program (GH5). This improvement in hemoglobin A1c assays contributes to better patient care and the use of A1c as a means of diagnosing and monitoring diabetes. Only the CAP makes such an extensive use of scientific committees and experts. When you rely on CAP PT, you’re assured that everything offered is based on the latest scientific advances, and an unrelenting drive for excellence.
    [Show full text]
  • MAX-ACT® Activated Clotting Time Test
    English Biological Improvements: The MAX-ACT Test For years, it has been assumed that the science behind an ACT test was relatively simple. ® MAX-ACT The premise has been: place an activator in the tube, add the blood sample, and a clot Activated Clotting Time Test will form. In actuality the formation of the clot is simple, but getting the clot to form within a certain timeframe, location, and strength is not as predictable. The novel, patented MAX-ACT test represents a new approach to ACT formulation with REF Cat. No. MAX-ACT the goal of standardizing contact activation for enhanced testing reliability. The original handheld ACT described a technique in which the ACT tube was inverted and mixed at INTENDED USE least once every 30 seconds throughout the testing period.1-3 This documented mixing The MAX-ACT Activated Clotting Time (ACT) test is intended for use in the performance interval continually “re-exposed” the blood sample to the large amounts of glass of the of the activated clotting time test, a whole blood coagulation assay commonly used to tube walls. The MAX-ACT uses a new formulation to recapture the original premise of monitor heparin anticoagulation during various medical and surgical procedures. MAX- the test by including glass beads as an additional activator thus offering constant blood ACT test tubes can be used in conjunction with the Actalyke instrument, the Actalyke exposure to glass. MINI and the Actalyke XL. MAX-ACT test tubes can also be used in conjunction with Further, the additional activators speed up the clotting cascade via the simultaneous ® Hemochron instruments.
    [Show full text]
  • Coagulation Monitoring Devices: Past, Present, and Future at the Point of Care
    Technological University Dublin ARROW@TU Dublin Articles School of Biological Sciences 2013 Coagulation Monitoring Devices: Past, Present, and Future at the Point of Care Leanne F. Harris Technological University Dublin, [email protected] Vanessa Castro-Lopez CIC microGUNE Tony J. Killard University of the West of England, Bristol Follow this and additional works at: https://arrow.tudublin.ie/scschbioart Part of the Biology Commons Recommended Citation Harris, L., Castro-Lopez, V. and Killard, T. J. (2013) Coagulation monitoring devices: Past, present, and future at the point of care. ,Trends in Analytical Chemistry, Vol. 50, October 2013. doi:/10.1016/ j.trac.2013.05.009 This Article is brought to you for free and open access by the School of Biological Sciences at ARROW@TU Dublin. It has been accepted for inclusion in Articles by an authorized administrator of ARROW@TU Dublin. For more information, please contact [email protected], [email protected]. This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 4.0 License Funder: Enterprise Ireland *Manuscript Click here to view linked References COAGULATION MONITORING DEVICES: PAST, PRESENT, AND FUTURE AT THE POINT OF CARE Leanne F. Harris, a* Vanessa Castro-López, b* and Anthony J. Killard a,c,d * Joint first authors aBiomedical Diagnostics Institute, National Centre for Sensor Research, Dublin City University, Dublin 9, Ireland. bCIC microGUNE, Goiru kalea 9, Polo Innovación Garaia, 20500, Arrasate-Mondragón, Spain. cDepartment of Applied Sciences, University of the West of England, Coldharbour Lane, Bristol BS16 1QY, UK. dCorresponding Author: Prof. Anthony J. Killard. Department of Applied Sciences, University of the West of England, Coldharbour Lane, Bristol BS16 1QY, UK.
    [Show full text]
  • Evaluating the Bleeding Patient: Point-Of-Care Tests
    procedures pro HEMOSTASIS Evaluating the Bleeding Patient: Point-of-Care Tests Marjory Brooks,DVM,Diplomate ACVIM,Comparative Coagulation Section,Animal Health Diagnostic Laboratory,Ithaca,New York EMORRHAGE is a common chief complaint that prompts veterinary attention. Although the cause Hof hemorrhage is often apparent from physical examination alone, some cases require diagnostic testing to help differentiate blood loss due to a breach in blood vessel integrity from a systemic failure of normal hemostatic processes. Bleeding diatheses are broadly classified as defects of platelet plug formation (primary hemostasis) or fibrin clot formation (secondary hemostasis). While there is no single “global” test for hemostasis, simple point-of-care tests can be done to detect the primary and secondary hemostatic defects often encountered in clinical practice. Estimation of platelet count from a stained blood smear readily identifies thrombocytopenia, the most com- mon canine and feline hemostatic abnormality. The ACT is a screening test of the intrinsic and common coagulation pathways, and a prolonged ACT is found in most patients with clinically significant coagulation factor deficiencies. The BMBT is an in vivo test of primary hemostasis that can aid in identifying patients with severe platelet dysfunction and severe von Willebrand’s disease. The following discus- sion describes the procedures for performing these screen- ing tests. Point-of-Care Tests for Hemostasis • Platelet Estimate from Blood Smear • Activated Clotting Time • Buccal Mucosa
    [Show full text]
  • Activated Clotting Time
    HOW TO Activated clotting time . using MAX-ACT tubes Please note this test does not measure the Prothrombin Time (PT), which is the recommended screening test for rat bait poisoning, nor has this test been validated for use in screening for rat bait poisoning. Gribbles Veterinary accepts no responsibility for the performance of this test and any possible outcomes. PT testing is available at your local Gribbles Veterinary laboratory. Intended use The Helena Laboratories MAX-ACT® Activated Clotting Time Test System is intended for use in the performance of a whole blood coagulation assay to monitor the use of anticoagulants such as heparin. ACT is commonly used (only) in veterinary medicine as an assessment of the intrinsic and common coagulation pathways. This test may detect only severe deficiencies of the intrinsic and common pathway factors. Storage and stability Actalyke MAX-ACT test tubes can be stored at room temperature (15-30°C). They must not be used past the expiration date that appears on the barcode label affixed to each test tube. These MAX-ACT tubes are NOT STERILE, so do not collect blood directly into the tube from the patient. Step-by-step method Note: These tubes are designed for use with an automated analyser. 1. Open the flip top of the selected Actalyke test tube. 2. Dispense 0.5mL of blood into the appropriate tube or fill to the line indicated on the tube. 3. Perform the next steps quickly and in order: 4. Press the START button on a stopwatch at the same time that blood is added to the tube.
    [Show full text]
  • Coagulation Tests
    Coagulation tests Erik Lerkevang Grove, Associate Prof, MD, PhD, FESC Department of Cardiology, Aarhus University Hospital, Denmark Disclosures • None related to this talk. • General disclosures: • Lecture fees from AstraZeneca, Baxter, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, MSD, Sysmex, and Pfizer. • Advisory board meetings for AstraZeneca, Bayer, Boehringer Ingelheim, and Bristol-Myers Squibb. Erik Lerkevang Grove Outline of talk: Coagulation tests • Coagulation system • Coagulation tests: why?, how?, when? • PT/INR • aPTT • ACT • Anti-Xa activity • Point-of-care testing: TEG & ROTEM • Evaluation of coagulation during treatment with NOACs • Conclusions Erik Lerkevang Grove Evaluating the coagulation system – why? • Unexplained bleeding • Pre- and perioperative testing • Monitoring of anticoagulant treatment • Research Erik Lerkevang Grove Coagulation system: traditional concept Hvas AM, Grove EL, Kristensen SD ESC Textbook of Intensive & Acute Cardiovascular Care, Oxford University Press, 2015 Coagulation system: current concept Modified from De Caterina et al, EHJ 2007. Prothrombin time (PT) and INR • PT measures the time [reference value: 11-13 seconds] it takes plasma to clot when exposed to tissue factor and reflects the ‘extrinsic’ and ‘common’ pathways of coagulation. • International normalized ratio (INR) [ref: 0.8-1.2] = (PT-patient/PT- normal)^ISI • Clinical use: bleeding, liver synthetic function, DIC, warfarin treatment. Erik Lerkevang Grove Activated partial thromboplastin time (aPTT) • The aPTT measures the time
    [Show full text]